Downregulated SIRT6 and upregulated NMNAT2 are associated with the presence, depth and stage of colorectal cancer

Qi,Jia; Cui,Chunhui; Deng,Quanwen; Wang,Lifeng; Chen,Rihong; Zhai,Duanyang; Xie,Lang; Yu,Jinlong

doi:10.3892/ol.2018.9400

Downregulated SIRT6 and upregulated NMNAT2 are associated with the presence, depth and stage of colorectal cancer

Authors:
- Jia Qi
- Chunhui Cui
- Quanwen Deng
- Lifeng Wang
- Rihong Chen
- Duanyang Zhai
- Lang Xie
- Jinlong Yu
View Affiliations

Affiliations: Department of General Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong 510280, P.R. China, Department of Pharmacy, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Gastroenterology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong 510280, P.R. China
Published online on: September 5, 2018 https://doi.org/10.3892/ol.2018.9400
Pages: 5829-5837
Copyright: © Qi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is an important cause of morbidity and mortality worldwide, and is difficult to detect in its early stages. Diagnostic and prognostic biomarkers are required, which may also be the basis for improving the targeted therapy for CRC. Sirtuin 6 (SIRT6) is a member of the sirtuin family of gene regulators, which have specific functions in genomic stability, gene transcription and energy metabolism in tumorigenesis. Nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) is a metabolic enzyme which can be deacetylated by sirtuins. In this study, tissue samples from 29 patients with histologically confirmed CRC of varying grade and stage were studied for SIRT6 and NMNAT2 expression by western blotting and reverse transcription‑quantitative polymerase chain reaction. Immunohistochemistry was performed for SIRT6 and NMNAT2 expression in 113 paired (CRC and adjacent) tissue sections. SIRT6 protein and mRNA expression levels were significantly reduced in CRC tissues; NMNAT2 protein and mRNA expression levels were significantly increased in CRC tissues (P<0.01). A negative correlation between the expression of SIRT6 and NMNAT2 in CRC tissue samples was identified (r=‑0.246, P<0.01). The reduced expression of SIRT6 and increased expression of NMNAT2 were associated with the tumor depth invasion, stage, differentiation grade (SIRT6 only) and the presence of lymph node metastasis (P<0.05). In conclusion, the findings of the present preliminary study demonstrated that the increased expression of NMNAT2 and reduced expression of SIRT6 may be associated with the progression of CRC. The downregulation of SIRT6 may promote the expression of NMNAT2. Further studies are indicated on the role of NMNAT2 and SIRT6 as potential diagnostic and prognostic biomarkers and as targets for therapy in CRC and other malignant tumors.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI
3	Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi RE and Corcione F: Worldwide burden of colorectal cancer: A review. Updates Surg. 68:7–11. 2016. View Article : Google Scholar : PubMed/NCBI
4	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
5	Rabeneck L, Horton S, Zauber AG and Earle C: Colorectal Cancer. In: Cancer: Disease Control Priorities, Third Edition (Volume 3)Gelband H, Jha P, Sankaranarayanan R and Horton S: The International Bank for Reconstruction and Development/The World Bank (C) 2015 International Bank for Reconstruction and Development/The World Bank. Washington (DC): 2015
6	Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, et al: Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA. 312:57–67. 2014. View Article : Google Scholar : PubMed/NCBI
7	Michan S and Sinclair D: Sirtuins in mammals: Insights into their biological function. Biochem J. 404:1–13. 2007. View Article : Google Scholar : PubMed/NCBI
8	Bruzzone S, Parenti MD, Grozio A, Ballestrero A, Bauer I, Del Rio A and Nencioni A: Rejuvenating sirtuins: The rise of a new family of cancer drug targets. Curr Pharm Des. 19:614–623. 2013. View Article : Google Scholar : PubMed/NCBI
9	Lerrer B, Gertler AA and Cohen HY: The complex role of SIRT6 in carcinogenesis. Carcinogenesis. 37:108–118. 2016. View Article : Google Scholar : PubMed/NCBI
10	Michishita E, McCord RA, Berber E, Kioi M, Padilla-Nash H, Damian M, Cheung P, Kusumoto R, Kawahara TL, Barrett JC, et al: SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature. 452:492–496. 2008. View Article : Google Scholar : PubMed/NCBI
11	Tennen RI and Chua KF: Chromatin regulation and genome maintenance by mammalian SIRT6. Trends Biochem Sci. 36:39–46. 2011. View Article : Google Scholar : PubMed/NCBI
12	Toiber D, Erdel F, Bouazoune K, Silberman DM, Zhong L, Mulligan P, Sebastian C, Cosentino C, Martinez-Pastor B, Giacosa S, et al: SIRT6 recruits SNF2H to DNA break sites, preventing genomic instability through chromatin remodeling. Mol Cell. 51:454–468. 2013. View Article : Google Scholar : PubMed/NCBI
13	Cea M, Cagnetta A, Adamia S, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, et al: Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 127:1138–1150. 2016. View Article : Google Scholar : PubMed/NCBI
14	Zhang G, Liu Z, Qin S and Li K: Decreased expression of SIRT6 promotes tumor cell growth correlates closely with poor prognosis of ovarian cancer. Eur J Gynaecol Oncol. 36:629–632. 2015. View Article : Google Scholar : PubMed/NCBI
15	Yu SS, Cai Y, Ye JT, Pi RB, Chen SR, Liu PQ, Shen XY and Ji Y: Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-κB-dependent transcriptional activity. Br J Pharmacol. 168:117–128. 2013. View Article : Google Scholar : PubMed/NCBI
16	Sundaresan NR, Vasudevan P, Zhong L, Kim G, Samant S, Parekh V, Pillai VB, Ravindra PV, Gupta M, Jeevanandam V, et al: The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat Med. 18:1643–1650. 2012. View Article : Google Scholar : PubMed/NCBI
17	Sebastian C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber D, et al: The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell. 151:1185–1199. 2012. View Article : Google Scholar : PubMed/NCBI
18	Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
19	Mayer PR, Huang N, Dewey CM, Dries DR, Zhang H and Yu G: Expression, localization, and biochemical characterization of nicotinamide mononucleotide adenylyltransferase 2. J Biol Chem. 285:40387–40396. 2010. View Article : Google Scholar : PubMed/NCBI
20	Jayaram HN, Kusumanchi P and Yalowitz JA: NMNAT expression and its relation to NAD metabolism. Curr Med Chem. 18:1962–1972. 2011. View Article : Google Scholar : PubMed/NCBI
21	Mouchiroud L, Houtkooper RH and Auwerx J: NAD⁺ metabolism: A therapeutic target for age-related metabolic disease. Crit Rev Biochem Mol Biol. 48:397–408. 2013. View Article : Google Scholar : PubMed/NCBI
22	Cairns RA, Harris IS and Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95. 2011. View Article : Google Scholar : PubMed/NCBI
23	Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, et al: The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell. 140:280–293. 2010. View Article : Google Scholar : PubMed/NCBI
24	Bauer I, Grozio A, Lasigliè D, Basile G, Sturla L, Magnone M, Sociali G, Soncini D, Caffa I, Poggi A, et al: The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem. 287:40924–40937. 2012. View Article : Google Scholar : PubMed/NCBI
25	Resch A and Langner C: Lymph node staging in colorectal cancer: Old controversies and recent advances. World J Gastroenterol. 19:8515–8526. 2013. View Article : Google Scholar : PubMed/NCBI
26	Van Cutsem E and Ducreux M: Colorectal and gastric cancer in 2015: The development of new agents and molecular classifications. Nat Rev Clin Oncol. 13:69–70. 2016. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Fukuda T, Wada-Hiraike O, Oda K, Tanikawa M, Makii C, Inaba K, Miyasaka A, Miyamoto Y, Yano T, Maeda D, et al: Putative tumor suppression function of SIRT6 in endometrial cancer. FEBS Lett. 589:2274–2281. 2015. View Article : Google Scholar : PubMed/NCBI
29	Zhang ZG and Qin CY: Sirt6 suppresses hepatocellular carcinoma cell growth via inhibiting the extracellular signal-regulated kinase signaling pathway. Mol Med Rep. 9:882–888. 2014. View Article : Google Scholar : PubMed/NCBI
30	Lin Z, Yang H, Tan C, Li J, Liu Z, Quan Q, Kong S, Ye J, Gao B and Fang D: USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation. Cell Rep. 5:1639–1649. 2013. View Article : Google Scholar : PubMed/NCBI
31	Kleszcz R, Paluszczak J and Baer-Dubowska W: Targeting aberrant cancer metabolism-The role of sirtuins. Pharmacol Rep. 67:1068–1080. 2015. View Article : Google Scholar : PubMed/NCBI
32	Xiong X, Wang G, Tao R, Wu P, Kono T, Li K, Ding WX, Tong X, Tersey SA, Harris RA, et al: Sirtuin 6 regulates glucose-stimulated insulin secretion in mouse pancreatic beta cells. Diabetologia. 59:151–160. 2016. View Article : Google Scholar : PubMed/NCBI
33	Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM and Cantley LC: Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science. 329:1492–1499. 2010. View Article : Google Scholar : PubMed/NCBI
34	Hsu PP and Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
35	Li H, Feng Z, Wu W, Li J, Zhang J and Xia T: SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non-small cell lung cancer cells through deacetylation of NMNAT2. Int J Oncol. 43:1420–1430. 2013. View Article : Google Scholar : PubMed/NCBI
36	Marquardt JU, Fischer K, Baus K, Kashyap A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, et al: Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology. 58:1054–1064. 2013. View Article : Google Scholar : PubMed/NCBI
37	Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, et al: Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 43:869–874. 2011. View Article : Google Scholar : PubMed/NCBI
38	Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, et al: Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 476:346–350. 2011. View Article : Google Scholar : PubMed/NCBI
39	Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, Soh BS, Sun LL, Tai BC, Nga ME, et al: Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell. 148:259–272. 2012. View Article : Google Scholar : PubMed/NCBI
40	Cantó C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, Andreux PA, Cettour-Rose P, et al: The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15:838–847. 2012. View Article : Google Scholar : PubMed/NCBI
41	Mégnin-Chanet F, Bollet MA and Hall J: Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cell Mol Life Sci. 67:3649–3662. 2010. View Article : Google Scholar : PubMed/NCBI